M&A Deal Summary

Vcanbio Acquires OriGene Technologies

On April 23, 2018, Vcanbio acquired life science company OriGene Technologies from Cathay Capital Private Equity

Acquisition Highlights
  • This is Vcanbio’s 1st transaction in the Life Science sector.
  • This is Vcanbio’s 1st transaction in the United States.
  • This is Vcanbio’s 1st transaction in Maryland.

M&A Deal Summary
Date 2018-04-23
Target OriGene Technologies
Sector Life Science
Buyer(s) Vcanbio
Sellers(s) Cathay Capital Private Equity
Deal Type Add-on Acquisition

Target

OriGene Technologies

Rockville, Maryland, United States
OriGene Technologies is a gene-centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene Technologies was founded in 1996 and is based in Rockville, Maryland.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vcanbio

Tianjin, China
Category Company
Founded 1992
Sector Life Science
Employees2,209
Revenue 1.6B CNY (2023)
DESCRIPTION

Vcanbio is a life science and technology innovative enterprise with the core vision of developing "precision medicine" (stock code: 600645). The company focuses on three major sectors: "precision prevention", "precision diagnosis" and "cell therapy". Its main business covers cell testing preparation and storage, research, production and sales of in vitro diagnostic raw materials, in vitro diagnostic reagents and equipment, and scientific research reagents such as biological genes, proteins and antibodies. Vcanbio was founded in 1992 and is based in Tianjin, China.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Maryland) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1

Seller(S) 1

SELLER

Cathay Capital Private Equity

Paris, France

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2006
PE ASSETS 5.0B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

Cathay Capital Private Equity SAS is a French Chinese private equity firm focused on acquiring businesses in France, Hong Kong, and China. Cathay looks to help Western companies leverage opportunities in China and help Chinese companies leverage Western best practices and partnerships. The Firm looks to invest in businesses generating €5 to €150 million in revenues. Areas of interest include retail, consumer goods, electrical equipment, medical devices, pharmaceuticals, animal healthcare, translation, food, consumer services, and software. Cathay Capital Private Equity SAS was formed in 2007 and is based in Paris. The firm has additional offices in New York and Shanghai.

DEAL STATS #
Overall 11 of 30
Sector (Life Science) 3 of 5
Type (Add-on Acquisition) 2 of 7
State (Maryland) 1 of 1
Country (United States) 2 of 2
Year (2018) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-09 Echosens

Paris, France

Echosens is a specialized diagnostic company providing non-invasive medical devices and services to support physicians in their diagnostic and monitoring of chronic liver diseases. Echosens was founded in 2001 and is based in Paris, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-04 NeoXam

Paris, France

NeoXam is a provider of investment accounting, investment management, and data management software solutions. NeoXam's customer base is made of large and medium asset management firms, investment banks, institutional investors, and securities services providers. NeoXam was founded in 2014 and is based in Paris, France.

Buy -
Mergr

Product

Company

Legal